The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
UAE President, VPs send Eid Al-Adha greetings to Arab, Islamic nations
UAE President performs Eid Al-Adha prayer at Sheikh Zayed Grand Mosque
UN Security Council condemns drone attack on Barakah Nuclear Power Plant
UAE and Russia discuss expanding strategic cooperation
Dubai to hold Eid Al-Adha prayers at 937 mosques
Arafat Day is for 'forgiveness, mercy, faith': H.H. Sheikh Mohammed
UAE floating hospital in Egypt treats more patients from Gaza
UAE President waives over AED 834 million in debt for Emiratis
